Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
- 109 Downloads
Nuclear metastasis-associated 1(MTA1) protein is an estrogen receptor co-repressor that regulates transcription via chromatin remodeling, and MTA1 messenger ribonucleic acid (mRNA) levels are elevated in several kinds of locally advanced and metastatic tumors relative to non-metastatic tumors. Previous studies in our laboratory mapped MTA1 into a region showing significantly lower LOH (loss of heterozygosity) in primary breast cancers with metastases compared to node-negative tumors, suggesting that epigenetic alterations of MTA1 affect metastatic potential. The present study examined immunohistochemical expression of the MTA1 protein in treated and untreated primary human breast cancers to study the relationship between MTA1 expression and clinical outcome. Node-negative tumors that overexpress MTA1 protein had recurrence risks similar to node-positive tumors. In multivariate analysis of untreated node-negative tumors, highest expression of MTA1 was associated with increased relapse risk (hazard ratio (HR)=2.72, p=0.0003 for multivariate analysis). Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies.
Keywordsbreast cancer MTA1 prognostic and predictive biomarker recurrence risk
Unable to display preview. Download preview PDF.
The authors thank Drs Gary Chamness and Jenny Chang for critical reading of the manuscript. This report was supported by Grants CA30195 and CA58183 from the National Cancer Institute, National Institutes of Health, Department of Human Services, and USAMRC Breast Cancer Training Grant, DAMD-17-99-1-9047873. This study was conducted under the aegis of Baylor College of Medicine Institutional Review Board Protocol 47830.
- 4.Allred DC, Clark GM, Tandon AK, McGuire WL, 1993 Immunohistochemistry on histological sections made from small (50 mg) samples of pulverized breast cancer J Histotechnol 16: 117–120Google Scholar
- 5.Lampkin SR, Allred DC, 1990 Preparation of paraffin blocks, sections containing multiple tissues samples using skin punch J Histotechnol 13: 121–123Google Scholar
- 10.Therneau TM, Grambsch PM, 2000 Modeling Survival Data: Extending the Cox Model Springer-Verlag, New YorkGoogle Scholar